drugset / Trial / NCT04868604
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Timeline
- Start
- 2021-08-11
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 64Cu-SAR-bisPSMA | Diagnostic / imaging agent | 200 mbq | — |
| Subject | 67Cu-SAR-bisPSMA | Unknown | — | — |